RAPT - Company ID 0001673772
The table below shows RAPT Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$52.41M | -$27.08M | -$18.60M | -$15.58M | -$13.91M | -$8.74M |
| Capital expenditure | $43.00K | $105.00K | $759.00K | $149.00K | $227.00K | $98.00K |
| Investing cash flow | -$57.06M | $15.89M | $25.31M | $23.84M | $12.41M | -$46.98M |
| Dividends paid | - | - | - |
RAPT Therapeutics, Inc. reported operating cash flow of -$83.30M for fiscal year 2024. That is up 14.2% from -$97.05M in fiscal 2023. Over the 7 fiscal years shown, operating cash flow declined from -$32.95M (FY 2018) to -$83.30M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $0.00 | $9.04M | $116.00K | $132.00K | $1.30M | $69.87M |